The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FAST Results for Febuxostat Safety in Patients with Gout

FAST Results for Febuxostat Safety in Patients with Gout

November 12, 2020 • By Keri Losavio

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9.

You Might Also Like
  • New Study Raises Cardiovascular Questions about Febuxostat for Gout
  • Study Finds Newer Gout Drug Poses Risk to Heart Patients
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Also By This Author
  • Gout: The State of the Science

Thomas MacDonald, MD, FRCP, MBChB

Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of Medicine, Scotland, U.K., presented the results from the so-called FAST study: “We did a prospective, randomized, open-label, blinded endpoint (PROBE) trial of febuxostat vs. allopurinol in patients with chronic gout in the U.K., Denmark and Sweden,” he said.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“As you all know, febuxostat and allopurinol are uric acid-lowering agents,” he said. Concerns about the cardiovascular safety of febuxostat have been raised, so the European Medicines Agency (EMA) recommended a post-authorization study. “The FDA [U.S. Food & Drug Administration] had also requested such a study, the CARES study, and it actually reported increased cardiovascular and all-cause deaths leading to an FDA warning and changes in treatment recommendations.”2

The Study
Between Dec. 20, 2011, and Jan. 26, 2018, 6,128 patients (mean age 71; 85.3% male; 33.4% with prior established cardiovascular disease) were randomized to receive allopurinol (n=3,065) or febuxostat (n=3,063), and were followed up for a median of four years, during which 5.5% and 6.2%, respectively, withdrew from all follow-up. “So this was really a long-term study,” he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Eligible patients were 60 years or older, were already being treated with allopurinol and had at least one additional cardiovascular risk factor. “We excluded strokes and MIs in the past six months, and severe heart failure,” Prof. MacDonald said.

“Allopurinol was increased—we titrated people up—if they weren’t at target at screening, and we did that by increasing the allopurinol dose at 100 mg every two weeks until they reached target or the maximum recommended dose … to achieve a serum uric acid level of less than 0.357 mmol/L [<6 mg/dL],” he said.

Patients were randomly assigned to continue allopurinol (at the optimized dose) or to start febuxostat at a dose of 80 mg daily, increasing to 120 mg, if necessary, to achieve a serum uric acid level of <0.357 mmol/L.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The primary outcome was the composite of hospitalization for non-fatal myocardial infarction/biomarker positive acute coronary syndrome, non-fatal stroke or cardiovascular death. This was ascertained via clinician or patient reports and by national healthcare records, post-mortem and death certification. The hazard ratio (febuxostat vs. allopurinol) in a Cox proportional hazards model was assessed for non-inferiority (limit of 1.3) in an on-treatment analysis and then by intention to treat.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Crystal Arthritis, Meeting Reports Tagged With: ACR Convergence 2020, ACR Convergence 2020 – Gout, CARES study

You Might Also Like:
  • New Study Raises Cardiovascular Questions about Febuxostat for Gout
  • Study Finds Newer Gout Drug Poses Risk to Heart Patients
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)